Clinical trials: Psychosis Nos/Other
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Schizophrenia, Schizoaffective Disorder
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, psychotic symptoms and social functioning in schizophrenia.
- Trial name
- OTS-12WK (NCT01394471)
- Testing
- Intranasal Oxytocin Spray
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of North Carolina, Chapel Hill
Psychosis, Bipolar Disorder
Young People and Illness Management and Recovery (IMR)
The study is a combined clinical patient outcome study and a health-services research sub-study. Illness management and recovery (IMR) constitutes an evidence-based practice with 11 modules focusing on personal recovery developed…
- Conditions
- Psychosis, Bipolar Disorder, Other Diagnoses and Conditions
- Trial name
- NCT04778085
- Testing
- Illness management and recovery, Semi-structured interviews
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- University Hospital, Akershus
Psychosis
A Combined Aerobic and Resistance Training Program for Adults With Psychotic Disorders
The study is a feasibility study of a combined high intensity aerobic and strenght exercise program for persons with psychotic disorders.
- Trial name
- TREPP (NCT05719116)
- Testing
- Physical exercise
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Solli Distriktspsykiatriske Senter
Schizophrenia Spectrum and Other Psychotic Disorders
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive…
- Trial name
- NCT03955549
- Testing
- Insight Enhancement Program (IEP), Metacognitive Training for Psychosis (MCT), Treatment As Usual (TAU)
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Agiad Psychiatry Hospital
Emotional Dysfunction, Psychosis
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
The principal aim of the study is to assess the efficacy of the Unified Protocol (UP) for the treatment of the comorbid symptomatology of patients with Ultra High Risk (UHR) for psychosis.
- Trial name
- NCT04929938
- Testing
- Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
- Where
- 2 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia, Schizotypal and Delusional Disorders
The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia
This study investigates the effects of using a smartphone app to support shared decision making (SDM) for people with schizophrenia-spectrum disorders in an outpatient treatment setting.
- Trial name
- NCT03554655
- Testing
- Momentum app
- Where
- 7 sites in Denmark
- Volunteers
- 194 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Psychosis, Cannabis Use
Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries.
- Trial name
- NCT07001878
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Psychosis
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with…
- Trial name
- TEA (NCT01119014)
- Testing
- Aripiprazole, Quetiapine
- Where
- 9 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anne Katrine Pagsberg
Schizophrenia; Psychosis
Evaluating a Novel Mobile App for Social Cognition in Psychosis
To develop, and then evaluate a mobile phone app to deliver therapy homework activities between group sessions (social cognition intervention) in individuals with psychosis.
- Trial name
- NCT04260763
- Testing
- Social Cognition Group, Novel Mobile App
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- King's College London
Schizophrenia, Psychosis
Optimizing Cognitive Remediation Outcomes in Schizophrenia
The purpose of this study is to drive an optimal response to neuroplasticity-based cognitive remediation in schizophrenia in order to maximize treatment response.
- Trial name
- CAST (NCT02105779)
- Testing
- Targeted Cognitive Training, Social Cognitive Training
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Chromosome 22q11.2 Deletion Syndrome
Genetics and Psychopathology in the 22q11 Deletion Syndrome
The purposes of this study are to: 1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and 2. identify genes that contribute to the occurrence of these symptoms.
- Trial name
- NCT00161109
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Schizophrenia and Disorders With Psychotic Features
Specialized Treatment Early in Psychosis (STEP)
The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis.
- Trial name
- STEP (NCT00309452)
- Testing
- Cognitive Behavioral Group Therapy, Cognitive remediation, Medications
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Yale University
Early Psychosis
Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis
The purpose of this study is to evaluate the impact of an antipsychotic medication decision aid and interpersonal and cognitive factors, such as attachment style and motivation, on emerging adults' ability to engage in shared…
- Trial name
- NCT04373590
- Testing
- Decision aid
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Temple University
Schizophrenia
Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
This will be a single site pilot study. 20 subjects with EPP (Early Phase Psychosis), defined as medical record documentation of the onset of clinically significant psychotic symptoms within the past 10 years, will be enrolled.
- Trial name
- rTMS-FPCC (NCT04309370)
- Testing
- 20 Hz rTMS
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Indiana University